DE60205376D1 - 2,6,9-substituierte purinderivate und ihre verwendung bei der behandlung proliferativer krankheiten - Google Patents

2,6,9-substituierte purinderivate und ihre verwendung bei der behandlung proliferativer krankheiten

Info

Publication number
DE60205376D1
DE60205376D1 DE60205376T DE60205376T DE60205376D1 DE 60205376 D1 DE60205376 D1 DE 60205376D1 DE 60205376 T DE60205376 T DE 60205376T DE 60205376 T DE60205376 T DE 60205376T DE 60205376 D1 DE60205376 D1 DE 60205376D1
Authority
DE
Germany
Prior art keywords
treatment
proliferative diseases
purine derivatives
substituted purine
pyrid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60205376T
Other languages
English (en)
Other versions
DE60205376T2 (de
Inventor
M Fischer
Mike Jarman
Edward Mcdonald
Bernard Nutley
Florence Raynaud
Stuart Wilson
Paul Workman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cyclacel Ltd
Cancer Research Technology Ltd
Original Assignee
Cyclacel Ltd
Cancer Research Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0115713A external-priority patent/GB0115713D0/en
Priority claimed from GB0120333A external-priority patent/GB0120333D0/en
Application filed by Cyclacel Ltd, Cancer Research Technology Ltd filed Critical Cyclacel Ltd
Publication of DE60205376D1 publication Critical patent/DE60205376D1/de
Application granted granted Critical
Publication of DE60205376T2 publication Critical patent/DE60205376T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
DE60205376T 2001-06-27 2002-06-27 2,6,9-substituierte purinderivate und ihre verwendung bei der behandlung proliferativer krankheiten Expired - Lifetime DE60205376T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0115713 2001-06-27
GB0115713A GB0115713D0 (en) 2001-06-27 2001-06-27 New purine derivatives
GB0120333A GB0120333D0 (en) 2001-08-21 2001-08-21 New purine derivatives
GB0120333 2001-08-21
PCT/GB2002/002962 WO2003002565A1 (en) 2001-06-27 2002-06-27 2,6,9-substituted purine derivatives and their use n the treatment of proliferative disorders

Publications (2)

Publication Number Publication Date
DE60205376D1 true DE60205376D1 (de) 2005-09-08
DE60205376T2 DE60205376T2 (de) 2006-04-06

Family

ID=26246255

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60205376T Expired - Lifetime DE60205376T2 (de) 2001-06-27 2002-06-27 2,6,9-substituierte purinderivate und ihre verwendung bei der behandlung proliferativer krankheiten

Country Status (7)

Country Link
US (1) US7612079B2 (de)
EP (1) EP1399446B1 (de)
JP (1) JP4381804B2 (de)
AT (1) ATE301123T1 (de)
DE (1) DE60205376T2 (de)
GB (1) GB2378180B8 (de)
WO (1) WO2003002565A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2741881B1 (fr) * 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
US6790958B2 (en) * 1996-08-02 2004-09-14 Robert T. Lum Purine inhibitors of cyclin dependent kinase 2 & IKBA
FR2806626B1 (fr) * 2000-03-22 2003-11-28 Centre Nat Rech Scient Utilisation de substances modulatrices de l'expression ou de la fonction d'une proteine impliquee dans le cycle cellulaire pour le traitement ou la prevention des lesions neurales aigues
GB0012528D0 (en) * 2000-05-23 2000-07-12 Univ Palackeho Triterpenoid derivatives
EP2336133A1 (de) 2001-10-30 2011-06-22 Conforma Therapeutics Corporation Purinanaloga mit HSP90-inhibierender Wirkung
GB0219052D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New puring derivatives
GB0219054D0 (en) 2002-08-15 2002-09-25 Cyclacel Ltd New purine derivatives
BRPI0414533A (pt) 2003-09-18 2006-11-07 Conforma Therapeutics Corp composto, composição farmacêutica, e, métodos para inibir um hsp90 e para tratar um indivìduo tendo um distúrbio mediado por hsp90
US7858813B2 (en) 2004-08-19 2010-12-28 Dsm Ip Assets B.V. Process for the rectification of mixtures of high-boiling air-and/or temperature-sensitive useful products
EP1799230B1 (de) 2004-08-27 2012-11-21 Cyclacel Limited Purin- und pyrimidin-cdk-hemmer und ihre verwendung zur behandlung von automimmunerkrankungen
GB0419416D0 (en) 2004-09-01 2004-10-06 Inst Of Ex Botany Ascr 4-Arylazo-3,5-Diamino-Pyrazole compounds and use thereof
EP2132208A1 (de) * 2007-03-28 2009-12-16 NeuroSearch AS Purinylderivate und ihre verwendung als kaliumkanalmodulatoren
GB0706632D0 (en) * 2007-04-04 2007-05-16 Cyclacel Ltd New purine derivatives
FR2920776B1 (fr) 2007-09-12 2012-09-28 Centre Nat Rech Scient Utilisation de derives de purine pour la fabrication d'un medicament
EP2330908A4 (de) * 2008-08-15 2011-11-23 Univ Georgetown Fluoreszente cdk-inhibitoren zur krebsbehandlung
WO2010103473A1 (en) * 2009-03-10 2010-09-16 Chu De Brest Method of treatment of polycystic diseases and chronic lymphocytic leukemia
GB201001075D0 (en) 2010-01-22 2010-03-10 Cyclacel Ltd Crystalline forms
RU2014149123A (ru) 2012-06-26 2016-08-20 Саниона Апс Фенилтриазольное производное и его применение для модуляции ГАМКА-рецепторного комплекса
WO2018138500A1 (en) 2017-01-26 2018-08-02 Cyclacel Limited Process for preparing purine derivatives
US20220160716A1 (en) * 2019-03-20 2022-05-26 Sorbonne Universite Roscovitine analogues and use thereof for treating rare biliary diseases
GB202000901D0 (en) 2020-01-22 2020-03-04 Cyclacel Ltd Process

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL277968A (de) * 1961-05-04
US3610721A (en) * 1969-10-29 1971-10-05 Du Pont Magnetic holograms
US3853676A (en) * 1970-07-30 1974-12-10 Du Pont Reference points on films containing curved configurations of magnetically oriented pigment
US3676273A (en) * 1970-07-30 1972-07-11 Du Pont Films containing superimposed curved configurations of magnetically orientated pigment
IT938725B (it) * 1970-11-07 1973-02-10 Magnetfab Bonn Gmbh Procedimento e dispositivo per otte nere disegni in strati superficiali per mezzo di campi magnetici
US3790407A (en) * 1970-12-28 1974-02-05 Ibm Recording media and method of making
US4011009A (en) * 1975-05-27 1977-03-08 Xerox Corporation Reflection diffraction grating having a controllable blaze angle
US4398798A (en) * 1980-12-18 1983-08-16 Sperry Corporation Image rotating diffraction grating
JPH0298811A (ja) * 1988-10-05 1990-04-11 Fuji Photo Film Co Ltd 磁気記録媒体
WO1990009178A1 (en) 1989-01-31 1990-08-23 Whitby Research, Inc. N6-substituted 9-methyladenines: a new class of adenosine receptor antagonists
US5192611A (en) * 1989-03-03 1993-03-09 Kansai Paint Co., Ltd. Patterned film forming laminated sheet
EP0556449B1 (de) * 1992-02-21 1997-03-26 Hashimoto Forming Industry Co., Ltd. Lackierung mit magnetisch hergestelltem Muster und lackiertes Produkt mit magnetisch hergestelltem Muster
GB9204015D0 (en) 1992-02-25 1992-04-08 Wellcome Found Therapeutic nucleosides
US5672410A (en) * 1992-05-11 1997-09-30 Avery Dennison Corporation Embossed metallic leafing pigments
US5991078A (en) * 1992-08-19 1999-11-23 Dai Nippon Printing Co., Ltd. Display medium employing diffraction grating and method of producing diffraction grating assembly
JP2655551B2 (ja) * 1992-09-09 1997-09-24 工業技術院長 微細表面形状創成法
US5688774A (en) 1993-07-13 1997-11-18 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
RU2143716C1 (ru) * 1993-07-16 1999-12-27 Лакофф Дисплей Корпорейшн Дисплей (варианты), матрица элементов (варианты), дифракционный пропускающий дисплей, дифракционный отражающий дисплей и способ получения дифрагированного излучения
US6033782A (en) * 1993-08-13 2000-03-07 General Atomics Low volume lightweight magnetodielectric materials
DE69422246T2 (de) * 1993-08-31 2000-05-11 Control Module Inc Gesichertes optisches Identifikationsverfahren und die hierzu erforderlichen Mittel
JP3396924B2 (ja) 1993-09-07 2003-04-14 日本曹達株式会社 活性汚泥のバルキング防止剤
DE4335308C2 (de) * 1993-10-16 1995-12-14 Daimler Benz Ag Kennzeichnung von Fahrzeugen zur Erschwerung von Diebstahl und oder unbefugter Veräußerung
DE69513313T2 (de) 1994-02-01 2000-07-13 Ajinomoto Kk Verfahren zur Herstellung von Nukleinsäurebasenderivaten
US5424119A (en) * 1994-02-04 1995-06-13 Flex Products, Inc. Polymeric sheet having oriented multilayer interference thin film flakes therein, product using the same and method
US6110923A (en) 1994-06-22 2000-08-29 Biochem Pharma Inc. Method for treating cancer using novel substituted purinyl derivatives with immunomodulating activity
DE69627195T2 (de) * 1995-11-01 2004-01-29 Novartis Ag Purinderivate und verfahren zu ihrer herstellung
FR2741881B1 (fr) * 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
GB9524862D0 (en) * 1995-12-06 1996-02-07 The Technology Partnership Plc Colour diffractive structure
US6790958B2 (en) * 1996-08-02 2004-09-14 Robert T. Lum Purine inhibitors of cyclin dependent kinase 2 & IKBA
WO1998016528A1 (en) * 1996-10-11 1998-04-23 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
EP1003746A1 (de) * 1997-08-07 2000-05-31 The Regents Of The University Of California Purin inhibitoren der protein kinasen, g proteine und polymerasen
US6573044B1 (en) * 1997-08-07 2003-06-03 The Regents Of The University Of California Methods of using chemical libraries to search for new kinase inhibitors
US6103361A (en) * 1997-09-08 2000-08-15 E. I. Du Pont De Nemours And Company Patterned release finish
US6168100B1 (en) * 1997-10-23 2001-01-02 Toyota Jidosha Kabushiki Kaisha Method for producing embossed metallic flakelets
EP1042509A1 (de) * 1997-12-24 2000-10-11 The Regents of the University of California Verfahren durch gebrauch an oligonukleotidarrays zum suchen von neuen kinase-inhibitoren
HUP0100931A3 (en) * 1998-02-26 2002-08-28 Aventis Pharma Inc 6,9-disubstituted 2-[trans-(-aminocyclohexyl)amino]purines and pharmaceutical compositions containing them
US6692031B2 (en) * 1998-12-31 2004-02-17 Mcgrew Stephen P. Quantum dot security device and method
CZ27399A3 (cs) * 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
IL144675A0 (en) * 1999-02-01 2002-05-23 Cv Therapeutics Inc PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IkB-α
US6627633B2 (en) * 1999-03-17 2003-09-30 Albany Molecular Research, Inc. 6-substituted biaryl purine derivatives as potent cyclin/CDK inhibitors and antiproliferative agents
US6808806B2 (en) * 2001-05-07 2004-10-26 Flex Products, Inc. Methods for producing imaged coated articles by using magnetic pigments
US6692830B2 (en) * 2001-07-31 2004-02-17 Flex Products, Inc. Diffractive pigment flakes and compositions
US6749936B2 (en) * 2001-12-20 2004-06-15 Flex Products, Inc. Achromatic multilayer diffractive pigments and foils
US6841238B2 (en) * 2002-04-05 2005-01-11 Flex Products, Inc. Chromatic diffractive pigments and foils
US6949644B2 (en) * 2001-10-12 2005-09-27 Irm Llc Methods for the synthesis of substituted purines
CA2463563A1 (en) * 2001-10-12 2003-04-17 Irm Llc Kinase inhibitor scaffolds and methods for their preparation
US20030229105A1 (en) * 2002-05-21 2003-12-11 Cyclacel Limited Treatment of autoimmune disorders
GB0219052D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New puring derivatives
GB0219054D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New purine derivatives

Also Published As

Publication number Publication date
GB2378180A8 (en) 2009-10-21
EP1399446A1 (de) 2004-03-24
JP2004521148A (ja) 2004-07-15
WO2003002565A1 (en) 2003-01-09
GB2378180B (en) 2004-01-28
ATE301123T1 (de) 2005-08-15
JP4381804B2 (ja) 2009-12-09
US7612079B2 (en) 2009-11-03
EP1399446B1 (de) 2005-08-03
GB2378180B8 (en) 2009-10-21
GB2378180A (en) 2003-02-05
US20050009846A1 (en) 2005-01-13
GB0214909D0 (en) 2002-08-07
DE60205376T2 (de) 2006-04-06

Similar Documents

Publication Publication Date Title
DE60205376D1 (de) 2,6,9-substituierte purinderivate und ihre verwendung bei der behandlung proliferativer krankheiten
MY135841A (en) Novel benzodioxoles
IL173032A0 (en) Pyridazine derivatives and their use as therapeutic agents
DE60315674D1 (de) Neue imidazopyridine und ihre verwendung
DE60318193D1 (en) Phenethanolaminderivate
TNSN04165A1 (en) Substituted hydroxyethylamines
NZ503407A (en) Anilide derivatives useful for treating inflammatory diseases
ATE320426T1 (de) Harnstoffderivate und ihre verwendung
ATE381537T1 (de) Formanilid-derivative als beta2-adrenorezeptor- agonisten
CA2401229A1 (en) Aryl fused azapolycyclic compounds
MXPA02007942A (es) Derivados de pirrolopirimidinona, procesos de preparacion y uso.
HK1074794A1 (en) The use of substituted cyanopyrrolidines for treating hyperlipidemia
PL396946A1 (pl) Pochodne pirazolu i kompozycje farmaceutyczne zawierające je oraz ich zastosowanie do leczenia HIV
NZ514487A (en) Carbamic acid derivatives and their use as metabotropic glutamate receptor ligands
UA85708C2 (ru) Лекарственные комбинации, содержащие бензоксазины, для лечения заболеваний дыхательных путей
MXPA04005886A (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitirptamina-6.
RS111204A (en) New compounds useful for the treatment of obesity,type ii diabetes and cns disorders
WO2003022216A3 (en) Biaryl substituted purine derivatives as potent antiproliferative agents
MY135218A (en) 2,6-quinolinyl and 2,6-naphthyl derivatives and their use in the treatment of vla-4 dependent diseases
WO2003022805A3 (en) Heterocycle substituted purines as antiproliferative agents
NO20020282L (no) Nytt difenyl-piperidinderivat
ATE389655T1 (de) Pyrimidinderivate
IL150817A0 (en) Pyrrole-type compounds, compositions, and methods for treating cancer or viral diseases
NZ524742A (en) Bridged piperazine derivatives
HUP0302255A2 (hu) Szulfonamidszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk

Legal Events

Date Code Title Description
8364 No opposition during term of opposition